A Phase 1 interventional study of SLV-313 SR in Healthy, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer. Terminated. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2009-08-04.
Sponsored by Wyeth is now a wholly owned subsidiary of Pfizer · Phase 1, Interventional, and Treatment
This is a randomized, inpatient, ascending multiple dose study to assess safety and tolerability of SLV-313 SR tablets administered orally to subjects with schizophrenia and schizoaffective disorder.
3,471 studies on the registry are indexed under Schizophrenia; 472 are open to participants now.
This study's planned enrollment of 32 is below the median of 70 across 2,872 interventional studies indexed under Schizophrenia.
Browse Schizophrenia studies →Wyeth is now a wholly owned subsidiary of Pfizer is the lead sponsor of 472 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Drug: SLV-313 SR
Drug: SLV-313 SR
Drug: SLV-313 SR
Drug: SLV-313 SR
sustained release tablets taken once daily for 14 days
Observe safety and tolerability
Time frame: 25 days
PK and PD profile
Time frame: 25 days
No study locations are listed for this record.
This study is terminated, as verified in Aug 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Wyeth is now a wholly owned subsidiary of Pfizer